Is Novo Nordisk A/S (NVO) a Buy, Sell, or Hold?
Novo Nordisk A/S
NYSE:NVO
$49.07 USD
-$0.21 (-0.43%)
- Volume
- 6.62M
- Average Volume
- 14.63M
- Market Capitalization
- $218.06B
- P/E Ratio
- 11.65
- Dividend Yield
- 3.66%
- Price Target
- $45.00
- Year High
- $71.80
- Year Low
- $35.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.42
- Current Ratio
- $0.79
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Maziar Mike Doustdar |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | NVO |
| CUSIP | 670100205 |
| CIK | 0000353278 |
| Web | https://www.novonordisk.com |
| Phone | 45 44 44 88 88 |
| Currency | USD |
| Employees | 77406 |
| Country | DK |
Liquidity
| Debt-to-Equity Ratio | 0.72 |
| Payout Ratio | 0.42 |
| Current Ratio | 0.79 |
| Quick Ratio | 0.56 |
| Cash Ratio | 0.09 |
Sales & Book Value
| Annual Sales | $309.06B |
| Price / Sales | 4.33 |
| Cash Flow | 6.98 |
| Price / Cash Flow | 45.77 |
| Price / Book | 6.99 |
Price Target and Rating
| Average Stock Price Forecast | $45.00 |
| High Stock Price Forecast | $45.00 |
| Low Stock Price Forecast | $45.00 |
| Forecast Upside/Downside | 9.04% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 39 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $23.03 |
| Trailing P/E Ratio | 11.65 |
| PEG Ratio | 0.70 |
| P/E Growth | 0.70 |
| Net Income | $102.43B |
| Net Margin | 37.20% |
| Pretax Margin | 47.49% |
| Return on Equity | 66.36% |
| Return on Assets | 21.81% |
Financials Score
| AltmanZ Score | 4.39 |
| Piotroski Score | 5.00 |
| Working Capital | -47.84B |
| Total Assets | 559.22B |
| Ebit | 164.14B |
| Market Cap | 1.44T |
| Total Liabilities | 356.16B |
Poll Results
About Novo Nordisk A/S (NYSE:NVO) Stock
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its cor ... e pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
2026-07-14 20:00:00
The market leader in obesity shots, Lilly hasn't made a major dent in the pill market yet.
How To Build A $50,000 Dividend Portfolio In Today's Market
2026-07-13 13:45:49
The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize a diversified mix of ETFs and individual stocks across sectors, balancing dividend income, growth, and capital appreciation while mitigating downside risk. Key metrics include a 3.75% weighted average dividend yield, low payout ratios, and low beta factors, supporting long-term portfolio resilience.
NVO DCF Analysis: Intrinsic Value $90 vs Price $49
2026-07-13 07:26:00
On July 13, 2026, we delve into the DCF analysis for Novo Nordisk AS (NVO), a company that has experienced notable price fluctuations recently. Over the past ye
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026
2026-07-11 09:15:00
Novo Nordisk is helping lead the way in the GLP-1 weight-loss niche. Realty Income is a real estate giant built to pay reliable dividends.
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
2026-07-11 08:00:01
Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss. The biotech company is in the early stages of developing an experimental implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
2026-07-10 11:16:06
Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
2026-07-10 10:01:23
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
2026-07-09 08:46:09
Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly. NVO's Wegovy pill outpaces Eli Lilly's Foundayo in new-to-brand prescriptions, driven by superior weight loss efficacy and fewer drug interaction restrictions. Despite setbacks, NVO is advancing late-stage candidates like CagriSema, UBT251, and zenagamtide, aiming to rival Eli Lilly's next-generation assets by the early 2030s.
Frequently Asked Questions
-
What is the current Novo Nordisk A/S (NVO) stock price?
-
Novo Nordisk A/S(NYSE:NVO) stock price is $49.07 in the last trading session. During the trading session, NVO stock reached the peak price of $71.8 while $35.12 was the lowest point it dropped to. The percentage change in NVO stock occurred in the recent session was --0.43% while the dollar amount for the price change in NVO stock was -$-0.21.
-
NVO's industry and sector of operation?
-
The NYSE listed NVO is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of NVO?
-
Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board
Emil Kongshøj Larsen | EVP of International Operations & Member of Management Board
Jamey Millar | Executive Vice President of US Operations & Member of Management Board
John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board
Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board -
How many employees does NVO have?
-
Number of NVO employees currently stands at 77406. NVO operates from Novo Alle 1, Bagsvaerd, CR 2880, DK.
-
Link for NVO official website?
-
Official Website of NVO is: https://www.novonordisk.com
-
How do I contact NVO?
-
NVO could be contacted at phone #45 44 44 88 88 and can also be accessed through its website. NVO operates from Novo Alle 1, Bagsvaerd, CR 2880, DK.
-
How many shares of NVO are traded daily?
-
The average number of NVO shares traded daily for last 3 months was 14.63M.
-
What is the market cap of NVO currently?
-
The market value of NVO currently stands at $218.06B with its latest stock price at $49.07